Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LipocineSTU:2VT0 46 Days Payable is 50.03 as of Jun. 2026, which is 31% above its 10-year median of 38.06. GuruFocus rates STU:2VT0 with a GF Score™ of 46/100 and a GF Value™ of €2.45. The stock has 4 warning signs investors should review. Among 704 Biotechnology companies, Lipocine ranks better than 58.52% on this metric.
Lipocine's average Accounts Payable for the
three
months ended in Jun. 2026 was €0.97 Mil. Lipocine's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €1.77 Mil.
Hence, Lipocine's Days Payable for the
three
months ended in Jun. 2026 was 50.03.
The historical rank and industry rank for Lipocine's Days Payable or its related term are showing as below:
STU:2VT0'
s Days Payable Range Over the Past 10 Years
Min: 14 Med: 38.06 Max: 161.67
Current: 161.67
During the past 13 years, Lipocine's highest Days Payable was 161.67. The lowest was 14.00. And the median was 38.06.
STU:2VT0's Days Payable is ranked better than 58.52% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs STU:2VT0: 161.67
Lipocine's Days Payable
increased
from Jun. 2025 (17.65) to Jun. 2026 (50.03).
It may suggest that Lipocinedelayed paying its suppliers.
The historical data trend for Lipocine's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2VT0 vs NXTC, VYNE, QNCX: Days Payable Comparison
For the Biotechnology subindustry, Lipocine's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipocine Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipocine's Days Payable distribution charts can be found below:
* The bar in red indicates where Lipocine's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Lipocine's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipocine (STU:2VT0) has a Days Payable of 50.03 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lipocine and its competitors. This is 31% above median its historical median of 38.06. Over the past decade, Lipocine's Days Payable has ranged from 14.00 to 161.67. According to the industry distribution chart, Lipocine ranks #292 out of 704 companies in the Biotechnology industry, placing it in the top 41.5%.
Is Lipocine's Days Payable too high?
Lipocine's current Days Payable of 50.03 is 31% above median its 10-year median of 38.06. Over the past 10 years, this metric has ranged from a low of 14.00 to a high of 161.67. The Biotechnology industry median Days Payable is 112.72. Lipocine's value of 50.03 is 55.6% below this industry median. Based on the distribution chart, Lipocine ranks #292 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lipocine has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Lipocine's Days Payable compare to NXTC and VYNE?
According to the Biotechnology industry distribution chart, Lipocine ranks #292 out of 704 companies for Days Payable. This puts Lipocine in the upper half of its industry. The industry median Days Payable is 112.72. Lipocine's value of 50.03 is 55.6% below this benchmark. Historically, Lipocine's own Days Payable has ranged from 14.00 to 161.67 over the past decade. While the company's 10-year median is 38.06 vs. the industry median of 112.72, Lipocine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipocine's current Days Payable of 50.03 is 55.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Lipocine and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipocine's current Days Payable is 50.03, which is 31% above median its own 10-year median of 38.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipocine stock overvalued right now?
Lipocine (STU:2VT0) has a current Days Payable of 50.03. The stock's GF Value™ is €2.45, compared to a current price of €3.94 — trading 61% above its estimated fair value. The current Days Payable is 50.03, which is 31% above median its 10-year median of 38.06 and 55.6% below the Biotechnology industry median of 112.72. Lipocine's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Lipocine (STU:2VT0), the current Days Payable is 50.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipocine (STU:2VT0) Overvalued in 2026?
Based on GuruFocus' analysis, Lipocine stock appears to be overvalued.
The current stock price of €3.94 is trading 61% above its estimated GF Value™ of €2.45.
Key valuation signals for STU:2VT0:
Days Payable: 50.03 (31% above median its 10-year median of 38.06)
GF Value™: €2.45 vs. price of €3.94 (61% above fair value)
Industry Position: 55.6% below the Biotechnology median (#292 of 704)
No single metric tells the full story. See the STU:2VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
46GF Score
Get the complete analysis for STU:2VT0
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2VT0 has been successfully added to your 
